Somerset, N.J.– October 28, 2014 – Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the promotion of Australia Country General Manager, Mark Bisset, to President, Catalent Asia Pacific. He succeeds David Heyens who has announced that he plans to retire from Catalent on December 31st 2014.
“Mark assumes his new role at an exciting time of expansion in the region and we welcome him to the Executive Leadership Team,” commented John Chiminski, Catalent’s President and Chief Executive Officer. “We have made substantial investments in two joint ventures in China to serve our growing customer base there. Additionally, we are celebrating our 40th year in Japan with a new laboratory and the build-out of more manufacturing capacity, and are seeing strong market growth in these and other parts of the Asia Pacific region.”
Prior to joining Catalent, Mr. Bisset was Chief Executive Officer for Strides Europe, leading all commercial and manufacturing activities across multiple countries while based in Poland. He had previously spent four years as Chief Operating Officer for Strides’ Australian and Asian businesses, overseeing a number of acquisitions including the successful integration of the ex-Genepharm business. Before that, he held global business development and product management roles with Mayne Pharma Ltd., Amrad Pharmaceuticals Pty Ltd. and Bristol Myers Squibb.
A native of Melbourne, Australia, Mr. Bisset is a qualified pharmacist and earned a bachelor’s at Australia’s Victorian College of Pharmacy and a graduate diploma in business from Monash University.
Commenting on Mr. Heyens impending retirement, John Chiminski added, “I want to express my deep gratitude and respect for David’s service to Catalent. From when he joined R.P. Scherer Canada in 1995 as general manager of softgel, to ultimately becoming softgel business unit president in 2010, he has played a major role in our transformation into an advanced, drug delivery technology leader.”
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com